Merck Q2 2026 Earnings Beat Estimates With KEYTRUDA Growth

Merck & Co., Inc. delivered second-quarter 2026 results that exceeded Wall Street expectations, posting revenue of $16.6 billion and demonstrating continued strength across its oncology portfolio and animal health division. The pharmaceutical giant reported a non-GAAP loss per share of $0.13, beating the analyst consensus estimate of $0.27 by a significant margin. The quarter’s performance reflects robust execution across multiple therapeutic areas and growing contributions from newly launched products, even as the company absorbed substantial charges related to its recent acquisition of Terns.

The Rahway, New Jersey-based company achieved 5% worldwide sales growth in the second quarter, or 4% excluding foreign exchange impacts. Revenue came in at $16.6 billion, surpassing the consensus estimate of $16.41 billion. Chairman and Chief Executive Officer Robert M. Davis attributed the results to strong execution and growing contributions from new product launches, highlighting the company’s ability to maintain momentum across its diverse portfolio despite industry headwinds.

KEYTRUDA Franchise Maintains Growth Momentum

The company’s flagship oncology franchise continued its impressive trajectory, with KEYTRUDA and KEYTRUDA QLEX generating combined sales of $8.4 billion during the quarter, representing 5% growth year-over-year or 4% growth excluding foreign exchange. The newly launched extended-release formulation KEYTRUDA QLEX contributed $463 million to total sales, demonstrating strong initial uptake among patients and healthcare providers. This performance underscores the drug’s enduring market position as a cornerstone immunotherapy across multiple cancer indications.

The KEYTRUDA franchise remains critical to Merck’s financial performance, accounting for more than half of the company’s quarterly revenue. The successful launch of QLEX, an extended-dosing formulation designed to improve patient convenience, suggests the company has effectively extended the product lifecycle while maintaining competitive positioning in the rapidly evolving oncology market. Analysts view this transition as crucial for sustaining revenue growth as the original KEYTRUDA formulation faces increasing biosimilar competition in international markets.

WINREVAIR Demonstrates Exceptional Growth Trajectory

Another standout performer in the quarter was WINREVAIR, a recently launched treatment that generated sales of $588 million, representing remarkable 75% growth both on a reported basis and excluding foreign exchange impacts. The drug’s exceptional growth rate reflects strong commercial execution and robust demand for the therapy. WINREVAIR’s performance significantly exceeded many analysts’ expectations, suggesting the product may achieve blockbuster status faster than initially projected.

The rapid uptake of WINREVAIR demonstrates Merck’s ability to successfully commercialize innovative therapies in competitive therapeutic areas. The drug addresses a significant unmet medical need, and its strong early performance positions it as a potential major revenue contributor in coming years. Industry observers note that the launch trajectory rivals some of the most successful pharmaceutical product introductions in recent history, providing validation for Merck’s research and development investments.

Animal Health Division Posts Solid Gains

Merck’s Animal Health division contributed $1.8 billion in sales during the second quarter, achieving 8% growth on a reported basis or 5% growth excluding foreign exchange. The division’s performance reflects continued demand for companion animal and livestock products amid favorable industry trends. This consistent growth from the Animal Health segment provides important revenue diversification for the company beyond its human pharmaceutical portfolio.

FDA Approval of LIPFENDRA Marks Major Regulatory Milestone

A highlight of the quarter came with the U.S. Food and Drug Administration’s approval of LIPFENDRA (enlicitide), marking a significant breakthrough as the first and only once-daily oral PCSK9 inhibitor approved to reduce LDL cholesterol in adults with hypercholesterolemia. The approval represents a major milestone in cardiovascular medicine, offering patients a convenient oral alternative to existing injectable PCSK9 inhibitors that require administration via injection.

“The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease,” said Davis.

The LIPFENDRA approval could position Merck to capture significant market share in the cholesterol-lowering market, where patient compliance has been challenged by the injectable administration route of competing PCSK9 inhibitors. The oral formulation addresses a key barrier to adoption and may expand the patient population eligible for this class of therapy, potentially creating a multibillion-dollar revenue opportunity.

Pipeline Advances Signal Future Growth Opportunities

Beyond the LIPFENDRA approval, Merck announced positive clinical data from multiple pipeline programs during the quarter. The company reported favorable results from the TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT) in certain patients with advanced or recurrent endometrial cancer. Additionally, Merck announced positive Phase 3 results from a once-weekly investigational oral HIV treatment regimen combining islatravir and lenacapavir, developed in collaboration with Gilead, which could transform HIV therapy adherence.

These pipeline developments demonstrate the breadth and depth of Merck’s research portfolio across oncology, infectious disease, and other therapeutic areas. The company’s ability to advance multiple programs simultaneously positions it to sustain long-term growth beyond its current marketed products.

Financial Impact of Terns Acquisition

The quarter’s financial results included substantial charges related to Merck’s acquisition of Terns Pharmaceuticals. The company reported a GAAP loss per share of $0.54, with both GAAP and non-GAAP losses incorporating a charge of $2.31 per share for the Terns acquisition. These one-time charges temporarily obscured the underlying operational performance but are expected to deliver long-term strategic value through access to Terns’ innovative pipeline assets.

Updated Full-Year Guidance Reflects Confidence

Merck raised and narrowed its full-year 2026 financial outlook, now expecting worldwide sales to range between $66.3 billion and $67.3 billion. The company projects non-GAAP earnings per share of $2.66 to $2.76, in line with the analyst consensus estimate of $2.76. The outlook includes charges of $2.43 per share related to the Terns acquisition, comprised of the one-time charge of $2.31 per share plus approximately $0.12 per share in financing costs and expenses to advance the acquired asset MK-4208 (formerly TERN-701).

Following the earnings announcement, Merck shares traded at $128.70, up 0.73%, as investors responded positively to the better-than-expected results and improved guidance. The stock’s performance reflects market confidence in the company’s execution capabilities and the strength of its commercial and pipeline assets heading into the second half of 2026.